DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS ® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Derek Jantz , Ph.D., Chief Scientific